Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis

被引：0
|
作者：
Cannon, Grant W. [1 ,2 ]
Teng, Chia-Chen [1 ,2 ]
He, Tao [1 ,2 ]
Leng, Jianwei [3 ,4 ]
Lu, Chao-Chin [1 ,2 ]
Tang, Derek [5 ]
Shah, Neel [5 ]
Harrison, David J. [5 ]
Sauer, Brian [1 ,2 ]
机构：
[1] Salt Lake City VA, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Salt Lake City VA, Salt Lake Citty, UT USA
[4] Univ Utah, Salt Lake Citty, UT USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
494
引用
收藏
页码：S213 / S213
页数：1
相关论文
共 50 条
  • [21] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [22] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    BioDrugs, 2001, 15 : 543 - 561
  • [23] USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS
    Singh, N.
    Peterson, A.
    Baraff, A.
    Bhatti, P.
    Gopal, A.
    Smith, N.
    Barton, J.
    Curtis, J.
    Li, C.
    Weiss, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1060 - 1061
  • [24] Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
    Singh, Namrata
    Peterson, Alexander
    Baraff, Aaron
    Gopal, Ajay
    Smith, Nicholas
    Barton, Jennifer
    Curtis, Jeffrey
    Weiss, Noel
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2381 - 2382
  • [25] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Liew, Jean
    Wysham, K.
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3333 - 3336
  • [26] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [27] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Syngle, Ashit
    Kaur, Sudeep
    Verma, Inderjeet
    Syngle, Tanya
    Syngle, Vijaita
    CLINICAL RHEUMATOLOGY, 2017, 36 (08) : 1715 - 1720
  • [28] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [29] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Ashit Syngle
    Sudeep Kaur
    Inderjeet Verma
    Tanya Syngle
    Vijaita Syngle
    Clinical Rheumatology, 2017, 36 : 1715 - 1720
  • [30] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Shimada, Hiromi
    Kameda, Tomohiro
    Kanenishi, Kenji
    Miyatake, Nobuyuki
    Nakashima, Shusaku
    Wakiya, Risa
    Kato, Mikiya
    Miyagi, Taichi
    Mansour, Mai Mahmoud Fahmy
    Hata, Toshiyuki
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
12345